Page title
Search SAMHSA Publications and Digital Products
Store Facets Summary
Main page content
Displaying results 1 - 5 of 5
Screening and Assessment of Co-Occurring Disorders in the Justice System
Published: June 2019
This report provides evidence-based practices for screening and assessment of adults in the justice system with mental illness, substance use disorders, or both. It discusses the importance of instrument selection for screening and assessment and provides detailed descriptions of recommended instruments.
TIP 48: Managing Depressive Symptoms in Substance Abuse Clients During Early Recovery
Published: January 2013
This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care.
Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders
Published: May 2012
This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.
Identifying Mental Health and Substance Use Problems of Children and Adolescents: A Guide for Child-Serving Organizations
Published: April 2012
This manual offers guidance and tools for identifying mental illness or substance use issues early in children and adolescents in various setting, such as in schools, the juvenile justice and child welfare system, and when receiving primary care.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Published: May 2010
This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.